We show that a significant decrease in PD-L1 and cell-stress gene expression can be achieved by employing certain combinations of two different agents, which suggests that combinational drug treatment could be beneficial not only for their enhanced potential to directly kill cancer cells, but also as a strategy to effect breast cancer cell killing in a way that evades the immunosuppressive effects of elevated PD-L1 expression and activation of cancer cell pro-survival programs. Here, CD274 is linked to breast carcinoma.